1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Immune Checkpoint Inhibitors Revenue
1.4 Market Analysis by Type
1.4.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 PD-1/PD-L1
1.4.3 CTLA-4
1.5 Market by Application
1.5.1 Global Immune Checkpoint Inhibitors Market Share by Application: 2021-2026
1.5.2 Lung Cancer
1.5.3 Colorectal Cancer
1.5.4 Breast Cancer
1.5.5 Prostate Cancer
1.5.6 Melanoma
1.5.7 Blood Cancer
1.5.8 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Immune Checkpoint Inhibitors Market
1.8.1 Global Immune Checkpoint Inhibitors Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Immune Checkpoint Inhibitors Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Immune Checkpoint Inhibitors Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Immune Checkpoint Inhibitors Sales Volume Market Share by Region (2015-2020)
3.2 Global Immune Checkpoint Inhibitors Sales Revenue Market Share by Region (2015-2020)
3.3 North America Immune Checkpoint Inhibitors Sales Volume
3.3.1 North America Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.3.2 North America Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Immune Checkpoint Inhibitors Sales Volume
3.4.1 East Asia Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.5.1 Europe Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.6.1 South Asia Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.7.1 Southeast Asia Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.8.1 Middle East Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.9.1 Africa Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.10.1 Oceania Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.11.1 South America Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.11.2 South America Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Immune Checkpoint Inhibitors Sales Volume (2015-2020)
3.12.1 Rest of the World Immune Checkpoint Inhibitors Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Immune Checkpoint Inhibitors Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Immune Checkpoint Inhibitors Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Immune Checkpoint Inhibitors Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Immune Checkpoint Inhibitors Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Immune Checkpoint Inhibitors Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Immune Checkpoint Inhibitors Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Immune Checkpoint Inhibitors Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Immune Checkpoint Inhibitors Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Immune Checkpoint Inhibitors Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Immune Checkpoint Inhibitors Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Immune Checkpoint Inhibitors Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Immune Checkpoint Inhibitors Sales Volume Market Share by Type (2015-2020)
14.2 Global Immune Checkpoint Inhibitors Sales Revenue Market Share by Type (2015-2020)
14.3 Global Immune Checkpoint Inhibitors Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Immune Checkpoint Inhibitors Consumption Volume by Application (2015-2020)
15.2 Global Immune Checkpoint Inhibitors Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business
16.1 Bristol Myer Squibb
16.1.1 Bristol Myer Squibb Company Profile
16.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Specification
16.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Seattle Genetics
16.2.1 Seattle Genetics Company Profile
16.2.2 Seattle Genetics Immune Checkpoint Inhibitors Product Specification
16.2.3 Seattle Genetics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Roche / Genentech
16.3.1 Roche / Genentech Company Profile
16.3.2 Roche / Genentech Immune Checkpoint Inhibitors Product Specification
16.3.3 Roche / Genentech Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 AstraZeneca
16.4.1 AstraZeneca Company Profile
16.4.2 AstraZeneca Immune Checkpoint Inhibitors Product Specification
16.4.3 AstraZeneca Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 ArGEN-X
16.5.1 ArGEN-X Company Profile
16.5.2 ArGEN-X Immune Checkpoint Inhibitors Product Specification
16.5.3 ArGEN-X Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Merck & Co.
16.6.1 Merck & Co. Company Profile
16.6.2 Merck & Co. Immune Checkpoint Inhibitors Product Specification
16.6.3 Merck & Co. Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 MacroGenics
16.7.1 MacroGenics Company Profile
16.7.2 MacroGenics Immune Checkpoint Inhibitors Product Specification
16.7.3 MacroGenics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 NewLink Genetics
16.8.1 NewLink Genetics Company Profile
16.8.2 NewLink Genetics Immune Checkpoint Inhibitors Product Specification
16.8.3 NewLink Genetics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Incyte Corporation
16.9.1 Incyte Corporation Company Profile
16.9.2 Incyte Corporation Immune Checkpoint Inhibitors Product Specification
16.9.3 Incyte Corporation Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Pfizer
16.10.1 Pfizer Company Profile
16.10.2 Pfizer Immune Checkpoint Inhibitors Product Specification
16.10.3 Pfizer Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Sorrento Therapeutics
16.11.1 Sorrento Therapeutics Company Profile
16.11.2 Sorrento Therapeutics Immune Checkpoint Inhibitors Product Specification
16.11.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Celldex Therapeutics
16.12.1 Celldex Therapeutics Company Profile
16.12.2 Celldex Therapeutics Immune Checkpoint Inhibitors Product Specification
16.12.3 Celldex Therapeutics Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 GlaxoSmithKline
16.13.1 GlaxoSmithKline Company Profile
16.13.2 GlaxoSmithKline Immune Checkpoint Inhibitors Product Specification
16.13.3 GlaxoSmithKline Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Innate Pharma
16.14.1 Innate Pharma Company Profile
16.14.2 Innate Pharma Immune Checkpoint Inhibitors Product Specification
16.14.3 Innate Pharma Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 CureTech
16.15.1 CureTech Company Profile
16.15.2 CureTech Immune Checkpoint Inhibitors Product Specification
16.15.3 CureTech Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 GITR, Inc
16.16.1 GITR, Inc Company Profile
16.16.2 GITR, Inc Immune Checkpoint Inhibitors Product Specification
16.16.3 GITR, Inc Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Immutep
16.17.1 Immutep Company Profile
16.17.2 Immutep Immune Checkpoint Inhibitors Product Specification
16.17.3 Immutep Immune Checkpoint Inhibitors Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
17.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
17.4 Immune Checkpoint Inhibitors Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Immune Checkpoint Inhibitors Distributors List
18.3 Immune Checkpoint Inhibitors Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Immune Checkpoint Inhibitors (2021-2026)
20.2 Global Forecasted Revenue of Immune Checkpoint Inhibitors (2021-2026)
20.3 Global Forecasted Price of Immune Checkpoint Inhibitors (2015-2026)
20.4 Global Forecasted Production of Immune Checkpoint Inhibitors by Region (2021-2026)
20.4.1 North America Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.3 Europe Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.7 Africa Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.9 South America Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Immune Checkpoint Inhibitors Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Immune Checkpoint Inhibitors by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.2 East Asia Market Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.3 Europe Market Forecasted Consumption of Immune Checkpoint Inhibitors by Countriy
21.4 South Asia Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.5 Southeast Asia Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.6 Middle East Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.7 Africa Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.8 Oceania Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.9 South America Forecasted Consumption of Immune Checkpoint Inhibitors by Country
21.10 Rest of the world Forecasted Consumption of Immune Checkpoint Inhibitors by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer